👌 Barron's on "Blockbuster Drug

Top of the fold headline from Barron’s this weekend: At Last, Weight-Loss Drugs That Actually Work. They Could Be the Blockbusters of the Decade.

By Bill Alpert
Updated Aug. 12, 2022 9:10 pm ET / Original Aug. 12, 2022 11:51 am ET


This is not a typical weight-loss story.

After all of the diet, supplement, and workout fads we’ve endured, we’re about to have drugs that are safe and effective. They’re our best hope yet for stemming the obesity epidemic that threatens the lives of 100 million Americans and half a billion people worldwide.

No one has ever seen the kind of weight loss achieved by these new drugs, known as incretins. In scientific studies, they have let people safely shed more than 20% of their weight. Incretins could become the best-selling drugs in pharmaceutical history for their competing developers, Novo Nordisk (ticker: NVO) and Eli Lilly (LLY). The companies’ stock market valuations reflect high hopes. But those hopes are merited.

I will be looking over the calls for Lily and Norvo Nordisk this weekend. If anybody beats me to it, throw down your fave looks at the calls. I’ll bring up the charts later. Just last week I almost bought some $LLY calls, but the volume wasn’t large enough to satisfy my tastes. That should change this coming week with this highly placed article from Barron’s this past weekend.


$LLY and $NVO charts

$LLY daily chart (next earnings 3 NOV 22)


$LLY weekly chart


$LLY monthly chart


$NVO daily chart (next earnings 2 NOV 22)


$NVO weekly chart


$NVO monthly chart


LLY 330 Call Oct 21 2022 Got in at $7.51 per share. Last sale was at $9.02.

I’m letting this one ride for another day. I would love to see the volume catch fire today.